The Global South political economy of health financing and spending landscape – history and presence

  • Mihajlo Jakovljevic
    Institute of Comparative Economic Studies, Hosei University Faculty of Economics, Tokyo, Japan
  • Yansui Liu
    Institute of Geographic Sciences and Natural Resources Research (IGSNRR), Chinese Academy of Sciences, Beijing, China
  • Arcadio Cerda
    Faculty of Economics and Business, University of Talca, Talca, Chile
  • Marta Simonyan
    Department of Pharmaceutical Management, Yerevan State Medical University, Yerevan, Armenia
  • Tiago Correia
    Global Health and Tropical Medicine, Instituto de Higiene e Medicina Tropical, Universidade Nova de Lisboa, Lisboa, Portugal
  • Richard M. Mariita
    Microbial BioSolutions, Troy, NY, USA
  • Ajantha Sisira Kumara
    Department of Public Administration, University of Sri Jayewardenepura, Nugegoda, Sri Lanka
  • Leidy Garcia
    Faculty of Economics and Business, University of Talca, Talca, Chile
  • Kristijan Krstic
    COVID Hospital, Clinical Center Kragujevac, Kragujevac, Serbia
  • Romanus Osabohien
    Department of Economics and Development Studies, Centre for Economic Policy and Development Research (CEPDeR), Covenant University, Ota, Nigeria
  • Tran Khanh Toan
    Family Medicine Department, Hanoi Medical University, Hanoi, Vietnam
  • Chiranjivi Adhikari
    Indian Institute of Public Health Gandhinagar (IIPHG), Gandhinagar, India
  • Nguyen Thi Kim Chuc
    Family Medicine Department, Hanoi Medical University, Hanoi, Vietnam
  • Resham B. Khatri
    School of Public Health, University of Queensland, Brisbane, Australia
  • Vijay Kumar Chattu
    Department of Medicine, University of Toronto, Toronto, Canada
  • Liang Wang
    Department of Public Health, Robbins College of Health and Human Sciences, Baylor University, Waco, TX, USA
  • Tissa Wijeratne
    Department of Neurology and Stroke at Western Health, The University of Melbourne, St Albans, Australia
  • Eugene Kouassi
    Department of Economics, Université Félix Houphouët-Boigny, Abidjan, Côte d'Ivoire
  • Habib Nawaz Khan
    University of Science and Technology, Bannu, Pakistan
  • Mirjana Varjacic
    Department of Pathology of Pregnancy, University of Kragujevac, Kragujevac, Serbia

この論文をさがす

説明

The Global South nations and their statehoods have presented a driving force of economic and social development through most of the written history of humankind. China and India have been traditionally accounted as the economic powerhouses of the past. In recent decades, we have witnessed reestablishment of the traditional world economic structure as per Agnus Maddison Project data. These profound changes have led to accelerated real GDP growth across many LMICs and emerging countries of the Global South. This evolution had a profound impact on an evolving health financing landscape. This review revealed hidden patterns and explained the driving forces behind the political economy of health spending in these vast world regions. The medical device and pharmaceutical industry play a crucial role in addressing the unmet medical needs of rising middle class citizens across Asia, Latin America, and Africa. Domestic manufacturing has only been partially meeting this ever rising demand for medical services and medicines. The rest was complemented by the participation of multinational pharmaceutical industry, whose focus on investment into East Asia and ASEAN nations remains part of long-term market access strategies. Understanding of the past remains essential for the development of successful health strategies for the present. Political economy has been driving the evolution of health financing landscape since the establishment of early modern health systems in these countries. Fiscal gaps these governments face in diverse ways might be partially overcome with the spreading of cost-effectiveness based decision-making and health technology assessment capacities. The considerable remaining challenges ranging from insufficient reimbursement rates, large out-of-pocket spending, and lengthy lag in the introduction of cutting-edge technologies such as monoclonal antibodies, biosimilars, or targeted oncology agents, might be partially resolved only in the long run.

収録刊行物

被引用文献 (2)*注記

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ